IL12 is a potent proinflammatory cytokine with a range of different anti‐tumor activities, including activating and increasing the cytotoxicity of T‐cells and inhibiting the activities of immunosuppressive cells within the TME.[50] We also found that MCTN‐IRF5 treatment boosted huMDM secretion of proinflammatory TNF‐α by 9.2‐fold (Figure 5I). The gene discussed is IRF5; the disease is neoplasm.